

DAFTAR PUSTAKA

1. Suarjana I.N, Hamijoyo L, Suntoko B, Kasjmir Y.I, Handono K, Wijaya L.K. Lupus eritematosus dan sindrom antibodi antifosfolipid. dalam: Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setyohadi B, Syam A, ed. Buku ajar ilmu penyakit dalam Jilid III Edisi VI. Jakarta: Interna Publishing; 2015; 3331–77.
2. Diagnosis dan pengelolaan lupus eritematosus sistemik. Perhimpunan Reumatologi Indonesia. 2019. 1–129.
3. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. *Ann Rheum Dis*. 2022; 1–6.
4. Hamijoyo L, Candrianita S, Rahmadi AR, Dewi S, Darmawan G, Suryajaya BS, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia. *Lupus*. 2019;28:1604–9.
5. Direktorat Pencegahan dan Pengendalian Penyakit. Memahami program deteksi dini penyakit lupus eritematosus sistemik. 2018.
6. Carrasco MG, Pinto CM, Escarcega RO, Hernandez MJ, Morales IE, Realpozo PM et al. Osteoporosis in patient with systemic lupus erythematosus. *IMAJ*. 2009;11: 486–91
7. Barbulescu A, Vreju FA, Criveanu C, Rosu A, Ciurea P. Osteoporosis in Systemic Lupus Erythematosus – correlations with disease activity and organ damage. *Curr Health Sci J*. 2015; 41(2): 109–14
8. Wu B., Xu D. Causal relationship between systemic lupus erythematosus and osteoporosis: A mendelian randomization analysis. *Research square*. 2023:1-15.
9. Terkawi MA., Matsumae G., Shimizu T., Takahashi D., Kadoya K., Iwasaki N. Interplay between inflammation and pathological bone resorption : insight into recent mechanisms and pathways in related disease for future perspectives. *Int J Mol Sci*. 2022; 23 (3):1–2

10. Bambang S. Struktur dan metabolisme tulang. Dalam: Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setyohadi B, Syam A, ed. Buku Ajar Ilmu Penyakit Dalam Jilid III Edisi VI. Jakarta: Interna Publishing; 2015; 3423–39
11. Chi G, Qiu L, Ma J, Wu M, Zhang Y. The association of osteoprotegerin and RANKL with osteoporosis: a systematic review with meta-analysis. *Journal of Orthopaedic Surgery and Research*. 2023; 839(18): 1–7
12. Rojas M, Rodriguez Y, Leon K, Pacheco Y, Ampudia Y, Monsalve D, *et al*. Cytokine and inflammatory mediators in Systemic Lupus Erythematosus. *EMJ Rheumatol*. 2018;5(1): 83–92.
13. Rella, V, Rotondo C, Altomare A, Cantatore FP, Corrado A. Bone involvement in systemic lupus erythematosus. *Int. J. Mol. Sci*. 2022; 23, 5804 : 1–15
14. Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, *et al*. Interleukin 1 α : a comprehensive review on the role of IL-1 α in the pathogenesis and treatment of autoimmune and inflammatory diseases. *Autoimmun Rev*. 2021 Mar;20(3):102763.
15. Yang N, Liu Y. The role of the immune microenvironment in bone regeneration. *Int J Med Sci*. 2021; 18(16):3697–707.
16. Cheng R, Wu Z, Li M, Shao M, Hu T. Interleukin-1 β is a potential therapeutic target for periodontitis. *International Journal of Oral Science*. 2020;12(2): 1–9.
17. Kitani A, Hara M, Hirose T, Harigai M, Suzuki K, Kawakami M, *et al*. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. *Clin Exp Immunol*. 1992;88(1):75–83.
18. Hillion S, Garaud S, Devauchelle V, Bordron A, Berthou C, Youinou P, *et al*. Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus. *Immunology*. 2007;122(3):371–80.
19. Ding J, Su S, You T, Xia T, Lin X, Chen Z, *et al*. Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythrematosus: a meta-analysis. *Clinics (Sao Paulo)*. 2020: 75:e1801

20. Ragab AA, Nalepka JL, Bi Y, Greenfield EM. Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. *Am J Physiol Cell Physiol* 2002;283:C679–87.
21. O'Brien CA, Lin SC, Bellido T, Manolagas SC. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastic signals generated by IL-6-type cytokines. *J Cell Biochem* 2000;14:532–41.
22. Ralston S. Bone structure and metabolism. *Medicine Elsevier*. 2021; 49(9): 567–71
23. Kini U., Nandeesh B.N. Physiology of bone formation, remodeling and metabolism. Springer-Verlag Berlin Heidelberg; 2012.
24. Rowe P., Koller A., Sharma S. StatPearls Publishing ; Physiology, Bone Remodeling. 2023.
25. Martin TJ, Sims N. RANKL/OPG; Critical role in bone physiology. *Rev Endocr Metab Disord*. 2015: 1–9
26. Liu W, Zhang X. Receptor activator of nuclear factor - κ B ligand (RANKL)/ RANK / osteoprotegerin system in bone and other tissues. *Mol Med Rep* 2015; 11: 3212–18.
27. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. *Arch Biochem Biophys* 2008; 473: 139–46.
28. Nagy V, Penninger JM. The RANKL-RANK Story. 2015: 534–42
29. Catalina MD, Owen KA, Labonte AC, Grammer AC, Lipsky PE. The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus. *J Autoimmun*. 2020;110:102359.
30. Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human Systemic Lupus Erythematosus: A Cellular Perspective. *Trends Mol Med*. 2017;23:615–35.
31. Kementerian Kesehatan RI. Pedoman pengendalian penyakit lupus eritematosus sistemik (LES). 2016.
32. Suarjana IN. Immunopathogenesis lupus eritematosus sistemik. In: Buku Ajar Ilmu Penyakit Dalam. 6th ed. Interna Publishing; 2014: 3331–45.

33. Crow MK. Etiology and pathogenesis of systemic lupus erythematosus. In: Firestein GS, Budd, Gabriel SE, McInnes J.R. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia: Elsevier; 2017.
34. Hahn BH. Systemic lupus erythematosus. In: Harrison's Principles of Internal Medicine. 20th ed. Mc Graw Hill. 2515–26. p.
35. Kaneko N, Kurata M, Yamamoto T, Morikawa S, Masumoto J. The Role of interleukin-1 in general pathology. Inflammation and Generation. 2019;39(12):1–16.
36. Italiani P, Manca M, Angelotti F, Melillo D, Pratesi F, Puxeddu I, et al. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res Ther. 2018; 20(27): 2–10.
37. Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nature Review Rheum. 2016;12:1–11.
38. Zhan Y, Cheng L, Wu B, Ji L, Chen P, Li F, et al. Interleukin (IL)-1 family cytokines could differentiate primary immune thrombocytopenia from systemic lupus erythematosus-associated thrombocytopenia. Ann Transl Med. 2021;1–10
39. Dean G, Price J, Crawley E, Isenberg D. Cytokines and systemic lupus erythematosus. Ann Rheum Dis. 2015; 59: 243–51
40. Cigni A, Pileri P, Faedda R, Gallo P, Sini A, Satta A, et al. Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor α in active and quiescent systemic lupus erythematosus. J Investig Med. 2014; 62 (5): 825–9.
41. Mende R, Vincent F, Rathnayake R, Koelmeyer R, Lin E, Chang J, et al. Analysis of serum interleukin (IL)-1 β and IL-18 in systemic lupus erythematosus. Front Immunol. 2018; 9:1250.
42. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan E, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology. 2010;49(3):520–7.
43. Loftus S, Liu J, Berthier C, Gudjonsson J, Kermani M, Tsoi L, et al. Loss of interleukin-1 beta is not protective in the lupus-prone NZM2328 mouse model. Front Immunol. 2023;14:1–12

44. Aringer M, Smolen JS. Cytokine expression in lupus kidneys. *Lupus*. 2005;14(1):13–8
45. Iwata Y, Furuichi K, Kaneko S, Wada T. The role of cytokine in the lupus nephritis. *J Biomed Biotechnol*. 2011;1–13
46. Tanaka T, Kishimoto T. Targeting interleukin-6 : all the way to treat autoimmune and inflammatory diseases. *Int J Biol Sci*. 2012; 8(9): 1227–36.
47. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1 β and 6 but not transforming growth factor- β are essential for the differentiation of interleukin 17-producing human T helper cells. *Nat Immunol*. 2007;8(9):942–9
48. H. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. *Arthritis Rheum*. 2003;48(6):1521–9
49. I. Kuhihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. *J Immunol* 1990;144:4226–30.
50. Katarzyna P, Wiktor S, Ewa D, Piotr L. Current treatment of systemic lupus erythematosus: a clinician's perspective. *Rheumatol Int*. 2023; 43(8): 1395–407
51. Basta F, Fasola F, Triantafyllias, Schwarting A. Systemic Lupus Erythematosus (SLE) therapy : the old and the new. *Rheumatol ther*. 2020; 7(3): 433–46
52. Nair S, Bhadracha H, Patil A, Surve S, Joshi B, Balasinar N, Desai M. Association of OPG and RANKL gene polymorphisms with bone mineral density in Indian women. *Elsevier*. 2022;840:1–9
53. Coury, F.; Peyruchaud, O.; Machuca-Gayet, I. Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases. *Front. Immunol*. 2019.10.679.
54. Bultink, I.E.M. Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus. *Calcif. Tissue Int*. 2018, 102, 575–591

55. Ali R, Hammad A, Nahrery E, Hamdy N, Elhawary A, Eid R. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ration in children with systemic lupus erythematosus. *Lupus*. 2019;28(10): 1233–42
56. Bonfa AC, Seguro LP, Caparbo V, Bonfa E, Pereira R. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus. *Osteoporos Int*. 2015;26(5):1563–71
57. Fernandes D, Santos M, Perpetuo I, Fonseca J, Canhao H. Soluble receptor activator of nuclear factor kB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patient. *Arthritis Res Ther*. 2011;13(5):1–6
58. Fatoye F, Gebrye T, Mbada C. Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. *Rheumatology international*. 2022; 42:2097–2107
59. Arkema E, Saleh M, Simard J, Sjowall C. Epidemiology and damage accrual of systemic lupus erythematosus in central Sweden: a single-center population-based cohort study over 14 years from ostergotland country. *ACR open rheumatology*. 2023; 5(8):426–32
60. Rahayu D, Udijono A, Saraswati L, Martini M. Gambaran Tingkat stress penderita lupus eritematosus sistemik. *JIM*. 2021; 11(2); 59–62
61. Sistem Informasi dan Manajemen Rumah Sakit (SIMRS) RSUP Dr.M.Djamil Padang
62. Li H, Du X, Lv X, Hao Z, He L. Correlation between body mass index and disease activity in patients with systemic lupus erythematosus from china. *Research square*. 2024;1–18
63. Kriswiastiny R, Mustofa F, Prasetya T, Wajdi M. Hubungan aktivitas penyakit SLE (systemic lupus erythematosus) berdasarkan skor mex sledai terhadap IMT (index massa tubuh) di komunitas odapus kota bandar lampung. *MAHESA*. 2022; 2(2); 278–88
64. Correa-Rodriguez M, Pocovi-Gerardino G, Callejas JL, Rios R, Martin M, Cruz M, et al. The impact of obesity on disease activity, damage accrual,

- inflammation markers and cardiovascular risk factors in systemic lupus erythematosus. *Panminerva Med.* 2020;62(2):75–82
65. Yip C, Saria S, Petri M, Magder L. Predictors of the start of declining eGFR in patients with systemic lupus erythematosus. *Lupus.* 2020: 30(1);15-24
 66. Janardhana G, Kurniari P, Kambayana G. Hubungan antara kadar interleukin 1 serum dan laju filtrasi glomerulus pada lupus eritematosus sistemik. *Udaya Journal of Internal Medicine.* 2022: 6(2); 36–40
 67. Suharno S, Apriansyah A, Ahmad Z, Salim E, Indrajaya T, Bahar E. Relationship between interleukin 6 serum levels and degree of depression in systemic lupus erythematosus patients internal disease. *Bioscientia Medicina: Journal of Biomedicine and Translational Research.* 2021: 5(3); 295–306
 68. Ismael A, Alabassi H. The dynamic role of PD-1, vitamin D, RANKL, and sclerostin in Iraqi patients with systemic lupus erythematosus. *Ibn A-Haitham Journal for Pure and Applied Sciences.* 2024: 37(1); 9–18
 69. Hao S, Zhang J, Huang B, Feng D, Niu X, Huang W. Bone remodeling serum markers in children with systemic lupus erythematosus. *Pediatr Rheumatol Online.* 2022: 20(54);1–6
 70. Hao S, Zhang Y, Tong X, Ding F, Wang R, Zhang J, et al. Glucocorticoids on bone remodeling in systemic lupus erythematosus mice. *Pediatric research.* 2025: 1-9
 71. Tonny, Kambayana G, Putra T, Kurniari P. Kadar interleukin-17 (IL-17) serum berkorelasi dengan rasio receptor activator NF- κ B ligand/osteoprotegerin (RANKL/OPG) pada penderita sistemik lupus eritematosus. 2018: 2(1);1–4
 72. Wang Z, Ding L, Zhang S, Jiang T, Yang Y, Li R. Effect of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1B-stimulated human SW1353 chondrosarcoma cells. *International Journal of Molecular Medicine.* 2014; 1720–26
 73. Sufi S, Alipour S, Rabieepour M, Milani S, Naderi R. Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG) dan RANKL/OPG ration in mild and severe COVID-19. *BMC infectious Disease.* 2024: 24;1–9

74. Xu J, Yu L, Liu F, Wan L, Deng Z. The effect of cytokines on osteoblasts and osteoclasts in bone remodeling in osteoporosis: a review. *Frontiers in Immunology*. 2023: 14; 1–16
75. Omma T, Yucel C, Sertoglu E, Firat S, Culha C. The role of IL-6 and osteoprotegerin in bone metabolism in patients with Grave's disease. *Turk J Med Sci*. 2022: 52; 338–45

